Armed with $9.4 million in Series A funding and strong clinical and industry connections, Satisfai Health plans to launch Certai for research applications in 2025, then expand into broader clinical use. The company’s technologies come at a critical juncture, with diagnostic endoscopy volumes on the rise and IBD incidence increasing. By applying AI to granular, pixel-level data invisible to the human eye, Satisfai Health seeks to accelerate treatment efficacy, ease physician workloads, and open the door to predictive analytics and more targeted therapeutic approaches—signaling a new era in GI care.
Keep Reading
Add A Comment